A GLOBAL PHASE 2 TRIAL OF NANATINOSTAT AND VALGANCICLOVIR IN PATIENTS WITH RELAPSED/REFRACTORY EBV-POSITIVE PERIPHERAL T-CELL LYMPHOMAS (NAVAL-1 STAGE 1-2) | Publicación